Testing an APA program to improve outcomes in large B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 3 trial studies whether an APA program (an added supportive program during care) can improve event-free survival for people with diffuse large B-cell lymphoma. It may help by supporting patients during standard first-line treatment so they do better over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have diffuse large B-cell lymphoma, or a low-grade B lymphoma that has transformed into high-grade (not other lymphoma types)
- You are 65 or older
- You are starting first-line treatment (no prior full chemotherapy for this; only limited pre-treatment is allowed)
- Your overall health is good enough to do treatment (performance status 0–2) and you can take RCHOP
- Your heart function is adequate (left heart pumping strength, LVEF, is 50% or higher)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a specific treatment plan to see how well it works for adults with newly diagnosed non-Hodgkin lymphoma that has a high amount of disease. It may help by aiming to control lymphoma more effectively, especially when it is widespread.
This trial tests a new combination of drugs for people with a type of lymphoma called diffuse large B cell lymphoma, especially if you are older or not healthy enough for standard full-dose chemotherapy. The treatment includes two immunotherapy drugs (epcoritamab and polatuzumab) plus a reduced-intensity chemotherapy regimen (mini-CHP). The goal is to see if this combination is safe and effective for people who may not tolerate stronger treatments.
This trial studies the best way to use an early (frontline) stem cell transplant for high-risk, CD20-positive diffuse large B-cell lymphoma (DLBCL). It aims to improve outcomes by comparing treatment approaches designed for people with a higher risk score.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
This trial tests whether adding an extra targeted drug (called X) to the standard chemo (Pola-R-CHP) can help people with aggressive B-cell lymphoma that didn't respond well after the first round. It aims to improve outcomes for those who need a stronger treatment approach.
This trial tests different combinations of targeted drugs and chemotherapy for people newly diagnosed with a type of lymphoma called DLBCL. It aims to find which combination is more effective and safer.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.